Jean-Baptiste Lattouf1, Jenny J. Ko2, Margot K. Davis3, Christian Constance4, Geoffrey T. Gotto5
Canadian Journal of Urology, Vol.31, No.5, pp. 11977-11985, 2024
Abstract Introduction: Niraparib, a PARP1/2 inhibitor, is newly
approved in combination with abiraterone acetate (AA)
plus prednisone or prednisolone (niraparib/AA+P) for
the treatment of adult patients with BRCA-mutated,
treatment-naïve metastatic castration resistant prostate
cancer (mCRPC). Detailed guidance beyond the
prescribing information may be helpful in managing
the side effect profile and dosing practicalities of this
combination therapy.
Materials and methods: A panel of specialists convened to
design management algorithms for four common niraparib/
AA+P treatment-related adverse events (AEs) in mCRPC;
anemia, thrombocytopenia, hypertension, and nausea. The
algorithms build on Health Canada-approved prescribing
information to highlight practical considerations related… More >
Login
Register
